Author:
Robert Tedjasaputra Tjahjadi,Hatta Mochammad,Nasrum Massi Muhammad,Natzir Rosdiana,Patellongi Ilhamjaya,Simadibrata Marcellus,Masadah Rina,Luthfi Parewangi Muhammad,Prihantono ,Asadul Islam Andi,Bukhari Agussalim,Nariswati Rinda,Elisa Tedjasaputra Shirly,Tedjasaputra Vincent,Salim Jonathan
Abstract
Heterozygote relatives have approximately 80% lifetime colorectal cancer (CRC) risk. mRNA gene expression and Bayesian theorem can calculate CRC’s family risk through the initial pedigree proportion appended with conditional information. The study is the first to report such an application. The present cross-sectional and translational investigation tracked CRC patients’ tissue and blood measurement of adenomatous polyposis coli (APC) and MutS homolog (MSH)2 mRNA quantitative gene expressions, control matching, and ancestral analysis by pedigree and Bayesian theorem. Among 40 CRC patients, mean tissue level and hereditary cutoff of APC are 13,261 (670) fold-change (fc) and 12,195 fc, while 12,219 (756) fc and 11,059 fc for MSH2. A quarter of the CRC patients had a history of familial CRC. Meanwhile, four CRC patients and 10 probands were evaluated for recurrence risk via pedigree, quantitative PCR, and Bayesian analysis. We determined a cutoff point for hereditary mRNA quantitative expression. APC and MSH2 levels in the CRC subjects were significantly lower than controls. The Bayesian analysis builds ways to calculate relative risk in CRC patients’ family members and application in clinical practice.
Reference32 articles.
1. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010;138(6):2044-2058. DOI: 10.1053/j.gastro.2010.01.054
2. Giardiello FM. Hereditary colorectal cancer and polyp syndromes. In: Gearhart SL, Ahuja N, editors. Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer. Philadelphia: Elsevier; 2010. pp. 21-30. DOI: 10.1016/ B978-1-4160-4686-8.50008-7
3. Nussbaum R, McInnes R, Willard H. Cancer genetics and genomic. In: Thompson & Thompson Genetics in Medicine. 8th ed. Philadelphia: Elsevier; 2015. pp. 309-332
4. Nussbaum R, McInnes R, Willard H. Risk assessment and genetic counselling. In: Thompson & Thompson Genetics in Medicine. 8th ed. Philadelphia: Elsevier; 2015. pp. 333-348
5. Tranø G, Sjursen W, Wasmuth HH, Hofsli E, Vatten LJ. Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: A Norwegian population-based study. British Journal of Cancer. 2010;102(3):482-488. DOI: 10.1038/sj.bjc.6605509